12/5
09:11 am
teva
Teva Pharmaceutical Industries (NYSE:TEVA) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $35.00 price target on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $35.00 price target on the stock.
12/2
11:47 am
teva
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term [Yahoo! Finance]
11/30
09:05 am
teva
Why Hall Of Famer Terrell Davis Is Talking About The ‘Other TD' [Forbes]
Low
Report
Why Hall Of Famer Terrell Davis Is Talking About The ‘Other TD' [Forbes]
11/30
07:34 am
teva
With 72% ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), institutional investors have a lot riding on the business [Yahoo! Finance]
Low
Report
With 72% ownership in Teva Pharmaceutical Industries Limited (NYSE:TEVA), institutional investors have a lot riding on the business [Yahoo! Finance]
11/26
12:30 am
teva
Is Teva a Bargain After 27% Surge and Cost-Cutting Headlines? [Yahoo! Finance]
Medium
Report
Is Teva a Bargain After 27% Surge and Cost-Cutting Headlines? [Yahoo! Finance]
11/25
11:55 pm
teva
European Biosimilar Approvals Could Be a Game Changer for Teva Pharmaceutical Industries (TEVA) [Yahoo! Finance]
Medium
Report
European Biosimilar Approvals Could Be a Game Changer for Teva Pharmaceutical Industries (TEVA) [Yahoo! Finance]
11/25
08:10 am
teva
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Low
Report
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
11/25
08:03 am
teva
Why Analysts See Teva's Story Shifting With New Approvals and Rising Price Targets [Yahoo! Finance]
Low
Report
Why Analysts See Teva's Story Shifting With New Approvals and Rising Price Targets [Yahoo! Finance]
11/21
06:11 pm
teva
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December [Yahoo! Finance]
Low
Report
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December [Yahoo! Finance]
11/21
04:30 pm
teva
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
Low
Report
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
11/19
08:00 am
teva
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
Low
Report
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
11/18
03:33 am
teva
Carillon Chartwell Short Duration High Yield Fund Q3 2025 Commentary [Seeking Alpha]
Low
Report
Carillon Chartwell Short Duration High Yield Fund Q3 2025 Commentary [Seeking Alpha]
11/14
10:40 am
teva
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business [Seeking Alpha]
Low
Report
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business [Seeking Alpha]
11/12
06:02 am
teva
RNA Targeting Small Molecules Therapeutics Global Research Report 2025: 7.03 Billion Market Opportunities and Strategies to 2034 - Expansion in AI-driven Drug Discovery, Alliances, Emerging Markets [Yahoo! Finance]
Medium
Report
RNA Targeting Small Molecules Therapeutics Global Research Report 2025: 7.03 Billion Market Opportunities and Strategies to 2034 - Expansion in AI-driven Drug Discovery, Alliances, Emerging Markets [Yahoo! Finance]
11/10
04:41 pm
teva
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? [Yahoo! Finance]
Medium
Report
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now? [Yahoo! Finance]
11/9
07:03 pm
teva
How Recent Developments Are Rewriting the Story for Teva Pharmaceutical Industries [Yahoo! Finance]
Low
Report
How Recent Developments Are Rewriting the Story for Teva Pharmaceutical Industries [Yahoo! Finance]
11/7
07:53 pm
teva
Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations [Yahoo! Finance]
Low
Report
Teva (TEVA) Hits Multi-Year High as Q3 Strengthens FY25 Profitability Expectations [Yahoo! Finance]
11/7
07:00 pm
teva
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living [Yahoo! Finance]
Low
Report
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living [Yahoo! Finance]
11/7
06:00 pm
teva
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Low
Report
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
11/6
05:26 pm
teva
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $28.00. They now have an "overweight" rating on the stock.
Low
Report
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $28.00. They now have an "overweight" rating on the stock.
11/5
07:00 am
teva
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
High
Report
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
11/3
08:00 am
teva
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
Low
Report
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
10/31
09:00 pm
teva
Medication used by many older Americans recalled for contamination [Yahoo! Finance]
Low
Report
Medication used by many older Americans recalled for contamination [Yahoo! Finance]
10/31
04:53 pm
teva
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November [Yahoo! Finance]
Low
Report
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November [Yahoo! Finance]
10/31
04:30 pm
teva
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
Low
Report
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November